PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

This guideline provides recommendations regarding the role of poly(ADP-ribose) polymerase inhibitors in the management of epithelial ovarian, tubal, or primary peritoneal cancer, based on the best available evidence.

Journal of Clinical Oncology